Gerald A. Maguire, MD joins Peter Reitzes to discuss what speech-language pathologists need to know about the emerging medical treatments in stuttering.
StutterTalk is excited to announce that this StutterTalk episode or course will be available for 0.10 CEUs for approximately six months, free of charge, through the National Stuttering Association. For complete details regarding the continuing education units being offered by the National Stuttering Association, go to the National Stuttering Association’s CEU page.
Take the CEU Test Here.(expired May 15, 2014)
Show/Course Notes:
Title: What Speech-Language Pathologists Need to Know About the Emerging Medical Treatments in Stuttering
Objectives: At the conclusion of the program, the learner shall be able to:
Identify the new DSM 5 criteria for childhood onset fluency disorder (stuttering)
Summarize available pharmacologic treatments for stuttering and related conditions.
Cite how traditional speech therapy with people who stutter is commonly effected by the medical treatment of stuttering.
Presenter Bio — Gerald A. Maguire, MD, is Sr. Associate Dean of Medical Education, holds the Kirkup Endowed Chair in Stuttering Treatment and is Professor of Clinical Psychiatry at the University of California Irvine School of Medicine. Dr. Maguire is a regular guest on StutterTalk. His previous appearances are archived here. Contact Dr. Maguire directly via email: gerald.maguire@uci.edu.
Episode/Course Description: Stuttering has recently been reclassified in DSM 5 as Childhood Onset Fluency Disorder. Over the past decade, much has been learned regarding the neurophysiologic and genetic basis of stuttering. With such, methods for medical treatments have emerged. Such treatments can potentially be utilized when standard speech therapy techniques have not yielded full benefits or as an augmentation to such treatments.
Gerald Maguire, M.D., DFAPA, Psychiatrist, joins Peter Reitzes and Eric Jackson to discuss the pharmaceuticals Asenapine and Pagoclone, the placebo effect, the dopamine system, a case study regarding stuttering onset associated with streptococcal infection and much more.
GERALD MAGUIRE is a person who stutters, the director of the Kirkup Center for the Medical Treatment of Stuttering at the University of California, Irvine and has researched the medical treatment of stuttering for more than 15 years. Dr. Maguire is certified by the American Board of Psychiatry and Neurology, is a Distinguished Fellow of the American Psychiatric Association and is author of the new book Without Hesitation: Speaking to the Silence and the Science of Stuttering.
Gerald A. Maguire, M.D. joins Peter Reitzes and Eric Jackson at the National Stuttering Association’s 2010 annual conference in Cleveland, Ohio. We discuss Dr. Maguire’s wonderful new book Without Hesitation: Speaking to the Silence and the Science of Stuttering (available through the National Stuttering Association).
All proceeds from Without Hesitation are being generously donated by Dr. Maguire to the NSA and to the Kirkup Center for the Medical Treatment of Stuttering.
Dr. Gerald Maguire from the Kirkup Center for the Medical Treatment of Stuttering joins Peter Reitzes andEric Jacksonto discuss Pagoclone updates, the recently published Exploratory Randomized Clinical Study of Pagoclone, the potential marketing of Pagoclone, his work with Dr. Nan Bernstein Ratner on the DSM5 (the Diagnostic and Statistical Manual of Mental Disorders) and much more.
Gerald Maguire, M.D., joins Peter Reitzes and Eric Jackson to discuss stuttering and depression and to update the Pagoclone Phase IIB trial which is nearing its 8 month completion. Dr. Maguire is the director of The Kirkup Center for the Medical Treatment of Stuttering. The Center provides evaluations to individuals across the globe. As a non-profit center, scholarships are available to individuals who stutter who have limited means. Dr. Maguire is certified by the American Board of Psychiatry and Neurology and is a Distinguished Fellow of the American Psychiatric Association. Email stuttering@uci.edu.
Dr. Gerald Maguire from the Kirkup Center for the Medical Treatment of Stuttering joins Peter Reitzes to talk about pharmaceutical treatment options for children and teens who stutter. Dr. Maguire also discusses the current Pagoclone Phase IIb Trial and his upcoming presentations at the National Stuttering Association and FRIENDS conferences. Dr. Maguire reports that most of the Pagoclone testing sites have met enrollment which is surely due to the high level of “buzz” surrounding the current study. You may contact Dr. Maguire at gerald.maguire@uci.edu.
StutterTalk® is a 501 (c)(3) non-profit organization dedicated to talking openly about stuttering. StutterTalk is the first and longest running podcast on stuttering. Since 2007 we have published more than 700 podcasts which are heard in 180 countries.
15 Nov 2013
What Speech-Language Pathologists Need to Know About the Emerging Medical Treatments in Stuttering (Ep. 429)
Podcast: Play in new window | Download
Subscribe: Apple Podcasts | Google Podcasts | Stitcher | TuneIn | RSS
Gerald A. Maguire, MD joins Peter Reitzes to discuss what speech-language pathologists need to know about the emerging medical treatments in stuttering.
StutterTalk is excited to announce that this StutterTalk episode or course will be available for 0.10 CEUs for approximately six months, free of charge, through the National Stuttering Association. For complete details regarding the continuing education units being offered by the National Stuttering Association, go to the National Stuttering Association’s CEU page.
Take the CEU Test Here.(expired May 15, 2014)Show/Course Notes:
Title: What Speech-Language Pathologists Need to Know About the Emerging Medical Treatments in Stuttering
Objectives: At the conclusion of the program, the learner shall be able to:
Presenter Bio — Gerald A. Maguire, MD, is Sr. Associate Dean of Medical Education, holds the Kirkup Endowed Chair in Stuttering Treatment and is Professor of Clinical Psychiatry at the University of California Irvine School of Medicine. Dr. Maguire is a regular guest on StutterTalk. His previous appearances are archived here. Contact Dr. Maguire directly via email: gerald.maguire@uci.edu.
Episode/Course Description: Stuttering has recently been reclassified in DSM 5 as Childhood Onset Fluency Disorder. Over the past decade, much has been learned regarding the neurophysiologic and genetic basis of stuttering. With such, methods for medical treatments have emerged. Such treatments can potentially be utilized when standard speech therapy techniques have not yielded full benefits or as an augmentation to such treatments.
Presenter’s Financial Disclosures: Research Grants: Otsuka, Merck. Speaking/Consulting: Lilly, Novartis, Merck, Sunovion, Assurex, Lundbeck, Otsuka, Takeda